also known as ZN-c3

DRUG2 trials

Sponsors

K-Group Beta Inc., Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Conditions

Metastatic colorectal cancerrecurrent or persistent uterine serous carcinoma

Phase 1

PHASE Ib STUDY WITH THE COMBINATION OF LB−100 (PP2A INHIBITOR) AND AZENOSERTIB (WEE1 INHIBITOR) IN PATIENTS WITH METASTATIC COLORECTAL CANCER The COLLEE trial

SuspendedCTIS2024-511227-33-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingMetastatic colorectal cancer

Target: 43Updated: 2024-11-08

Phase 2

A Phase 2 Open-label, multicenter study to evaluate efficacy and safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma

CompletedCTIS2023-507324-23-00

K-Group Beta Inc.recurrent or persistent uterine serous carcinoma

Start: 2024-05-22End: 2025-10-23Target: 70Updated: 2024-04-11